Drug Profile
Research programme: histone deacetylase inhibitors - Clovis Oncology Italy/Karus Therapeutics
Alternative Names: 4800 research programme - EOS; E-162; HDAC inibitors - Clovis Oncology Italy/Karus Therapeutics; KA001; KAR-2261; Spiruchostatin analogues - Clovis Oncology Italy/Karus TherapeuticsLatest Information Update: 10 Apr 2018
Price :
$50
*
At a glance
- Originator Karus Therapeutics
- Developer EOS S.p.A.; Karus Therapeutics
- Class Depsipeptides
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Aug 2013 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 28 Aug 2013 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 19 Jan 2010 This research programme is still in active development